Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE Plus semaglutide in early Alzheimer's disease
NL-OMON58786Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Oral semaglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in Clinical Dementia Rating – Sum of Boxes score. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON58786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58786.